Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $66.58 Average Price Target from Analysts

by · The Cerbat Gem

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $66.5833.

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a research report on Friday, November 28th. Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a research report on Friday, December 5th. Wedbush upped their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, October 8th.

View Our Latest Research Report on Vera Therapeutics

Vera Therapeutics Stock Performance

VERA opened at $49.80 on Friday. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $32.05 and its 200-day moving average is $26.46. The stock has a market cap of $3.18 billion, a PE ratio of -12.48 and a beta of 1.21. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $50.16.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the business posted ($0.85) earnings per share. On average, analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insider Transactions at Vera Therapeutics

In other news, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VERA. Quarry LP boosted its position in shares of Vera Therapeutics by 25.0% in the first quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $60,000 after buying an additional 500 shares during the period. Virtus Investment Advisers LLC lifted its stake in Vera Therapeutics by 14.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after acquiring an additional 539 shares in the last quarter. Invesco Ltd. boosted its position in Vera Therapeutics by 2.0% during the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after acquiring an additional 550 shares during the period. Ameritas Investment Partners Inc. boosted its position in Vera Therapeutics by 13.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock worth $124,000 after acquiring an additional 615 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Vera Therapeutics by 2.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock valued at $744,000 after acquiring an additional 816 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

Read More